Pharmacotherapeutic report (t=4) on ranibizumab (Lucentis®) for the treatment of neovascular (wet) age-related macular degeneration (AMD) - Pegaptanib - Document - PDFSEARCH.IO

First Page	Meta Content
	Pharmacotherapeutic report (t=4) on ranibizumab (Lucentis®) for the treatment of neovascular (wet) age-related macular degeneration (AMD) Add to Reading List Document Date: 2013-02-27 06:00:00 Open Document File Size: 51,16 KB Share Result on Facebook Company AMD / / IndustryTerm ml solution / mg/ml solution / / MedicalCondition macular degeneration / / MedicalTreatment photodynamic therapy / / Product Lucentis / / SocialTag Macular degeneration Pegaptanib Verteporfin Photodynamic therapy Side effect Vascular endothelial growth factor Choroidal neovascularization Medicine Ranibizumab Bevacizumab

Pharmacotherapeutic report (t=4) on ranibizumab (Lucentis®) for the treatment of neovascular (wet) age-related macular degeneration (AMD)Add to Reading List